U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H24N2
Molecular Weight 244.3752
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of rel-trans-4-Amino-N-[(1R,2S)-2-phenylcyclopropyl]cyclohexanemethanamine

SMILES

N[C@H]1CC[C@H](CN[C@@H]2C[C@H]2C3=CC=CC=C3)CC1

InChI

InChIKey=VHNNYAVEBXCOSG-QCEMKRCNSA-N
InChI=1S/C16H24N2/c17-14-8-6-12(7-9-14)11-18-16-10-15(16)13-4-2-1-3-5-13/h1-5,12,14-16,18H,6-11,17H2/t12-,14-,15-,16+/m0/s1

HIDE SMILES / InChI
Molecular Formula C16H24N2
Molecular Weight 244.3752
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

ORY-1001 (known as RG 6016) is a Lysine Specific Demethylase 1 (LSD1, also known as KDM1A) inhibitor (IC50 <20nM) with high selectivity against related FAD dependent aminoxidases (MAO-A/B, IL4I1, KDM1B >100uM, SMOX 7uM). LSD1 is a histone eraser enzyme that removes methyl groups, specifically mono and demethylated H3K4 and H3K9, and by doing so regulates the expression of many genes important in the onset and progression of diseases such as cancer and neurodegenerative disorders. ORY-1001 is a lead drug candidate of Oryzon Genomics S.A. under development for the treatment of acute myeloid leukemia (AML) – phase I/II and small cell lung cancer (SCLC) – phase I. Oryzon has made significant progress with ORY-1001 over the past years.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Primary
Phase I
438
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
13.1 pg/mL
EXPERIMENT
https://ashpublications.org/blood/article/128/22/4060/113698/Safety-Phamacokinetics-PK-Pharmacodynamics-PD-and
140 μg/m² single, oral
dose: 140 μg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
ORY-1001 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
181.7 pg × h/mL
EXPERIMENT
https://ashpublications.org/blood/article/128/22/4060/113698/Safety-Phamacokinetics-PK-Pharmacodynamics-PD-and
140 μg/m² single, oral
dose: 140 μg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
ORY-1001 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
220 ug/m2 1 times / day multiple, oral
MTD
Dose: 220 ug/m2, 1 times / day
Route: oral
Route: multiple
Dose: 220 ug/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33052756
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/33052756
Other AEs: pneumonia, febrile neutropeni...
Other AEs:
pneumonia (grade 5, 1 pt)
febrile neutropeni (grade 3, 1 pt)
Sources:
https://pubmed.ncbi.nlm.nih.gov/33052756
140 ug/m2 1 times / day multiple, oral
Recommended
Dose: 140 ug/m2, 1 times / day
Route: oral
Route: multiple
Dose: 140 ug/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33052756
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/33052756
Disc. AE: thrombocytopenia...
AEs leading to
discontinuation/dose reduction:
thrombocytopenia (grade 4, 1 pt)
Sources:
https://pubmed.ncbi.nlm.nih.gov/33052756
AEs

AEs

AESignificanceDosePopulation
febrile neutropeni grade 3, 1 pt
220 ug/m2 1 times / day multiple, oral
MTD
Dose: 220 ug/m2, 1 times / day
Route: oral
Route: multiple
Dose: 220 ug/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33052756
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/33052756
pneumonia grade 5, 1 pt
220 ug/m2 1 times / day multiple, oral
MTD
Dose: 220 ug/m2, 1 times / day
Route: oral
Route: multiple
Dose: 220 ug/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33052756
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/33052756
thrombocytopenia grade 4, 1 pt
Disc. AE
140 ug/m2 1 times / day multiple, oral
Recommended
Dose: 140 ug/m2, 1 times / day
Route: oral
Route: multiple
Dose: 140 ug/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33052756
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/33052756
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYPs
29
P-gp
2052

HLM
34
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYPs
35
 no [IC50 >100 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
P-gp
2052
 no
HLM
34
 unlikely
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
Enamine
BBV-33522626
http://www.enaminestore.com/catalog/BBV-33522626
MolPort
MolPort-011-710-439
https://www.molport.com/shop/molecule-link/MolPort-011-710-439
PubMed

PubMed

TitleDatePubMed
Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.
2016
KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease.
2015
Patents

Patents

US2014256729
1

Sample Use Guides

In Vivo Use Guide
in rodent xenografts: Daily oral administration of doses <0.020 mg/kg
Route of Administration: Oral
In Vitro Use Guide
ORY-1001 is a Lysine Specific Demethylase 1 (LSD1, also known as KDM1A) inhibitor (IC50 <20nM) with high selectivity against related FAD dependent aminoxidases (MAO-A/B, IL4I1, KDM1B >100uM, SMOX 7uM). ORY-1001 does not inhibit non-related histone modifiers. Treatment of THP-1 (MLL-AF9) cells with ORY-1001, results in a time/dose dependent me2H3K4 accumulation at KDM1A target genes and concomitant induction of differentiation markers (EC50 me2H3K4 and FACS CD11b <1nM). Microarray analysis of treated THP-1 cells reveals differentiation towards a monocyte-like phenotype. ORY-1001 induces apoptosis in THP-1 and inhibits proliferation and colony formation of MV(4;11) (MLL-AF4) cells (EC50 <1nM).
Substance Class Chemical
Created
by admin
on Wed Apr 02 03:43:57 GMT 2025
Edited
by admin
on Wed Apr 02 03:43:57 GMT 2025
Record UNII
XC0UT08SNJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
rel-trans-4-Amino-N-[(1R,2S)-2-phenylcyclopropyl]cyclohexanemethanamine
Common Name English
CYCLOHEXANEMETHANAMINE, 4-AMINO-N-((1R,2S)-2-PHENYLCYCLOPROPYL)-, TRANS-REL-
Preferred Name English
Code System Code Type Description
PUBCHEM
66571534
Created by admin on Wed Apr 02 03:43:57 GMT 2025 , Edited by admin on Wed Apr 02 03:43:57 GMT 2025
PRIMARY
FDA UNII
XC0UT08SNJ
Created by admin on Wed Apr 02 03:43:57 GMT 2025 , Edited by admin on Wed Apr 02 03:43:57 GMT 2025
PRIMARY
CAS
1401966-39-9
Created by admin on Wed Apr 02 03:43:57 GMT 2025 , Edited by admin on Wed Apr 02 03:43:57 GMT 2025
PRIMARY
Related Record Type Details
LYSINE-SPECIFIC HISTONE DEMETHYLASE 1A
TARGET -> INHIBITOR
IC50
Related Record Type Details
Structure of rel-trans-4-Amino-N-[(1R,2S)-2-phenylcyclopropyl]cyclohexanemethanamine
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966